Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | DCLRE1A | Q6PJP8 | 1/20 | 0.43 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7330961 | 0.86 | HPGD (0.44) | HPGDBACE1KDM4ESMN1; SMN2HSD17B1 | |
| SCHEMBL5263743 | 0.84 | PDCD1 (0.48) | PDCD1CD274CYP1A2PTGS1DCLRE1A | |
| SCHEMBL2139060 | 0.84 | HPGD (0.42) | HPGDPDCD1CD274CYP1A2PTGS1 | |
| SCHEMBL7336718 | 0.82 | HPGD (0.42) | HPGDPTGS1KDM4EHSD17B1TNKS2 | |
| SCHEMBL7673877 | 0.82 | ALOX5 (0.44) | HPGDCYP1A2ALOX5ESR2HSD17B1 | |
| SCHEMBL2810201 | 0.81 | GSTP1 (0.54) | CYP1A2PTGS1MAPTGAASMN1; SMN2 | |
| SCHEMBL3148557 | 0.81 | DCLRE1A (0.47) | HPGDPDCD1CD274CYP1A2PTGS1 | |
| SCHEMBL27671603 | 0.80 | GAA (0.42) | HPGDPDCD1CD274CYP1A2PTGS1 | |
| SCHEMBL3784027 | 0.80 | TAAR1 (0.48) | HPGDCYP1A2PTGS1DCLRE1ADCLRE1B | |
| SCHEMBL6772346 | 0.80 | GAA (0.42) | HPGDCYP1A2PTGS1DCLRE1ADCLRE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021154966-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2021-08-05 | — | — | WO | disclosed |
| CN-101932325-B | Ido inhibitors | NEWLINK GENETICS | 2014-05-28 | — | — | CN | disclosed |
| US-20040167193-A1 | Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-08-26 | — | — | US | disclosed |
| US-6762197-B2 | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-07-13 | — | — | US | disclosed |
| US-20030119670-A1 | Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-06-26 | — | — | US | disclosed |
| US-6489487-B1 | AGRICULTURAL OR HORTICULTURAL FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| EP-1238975-A1 | DIFLUOROMETHYLTRIAZOLONE COMPOUNDS, USE OF THE SAME AND INTERMEDIATES FOR THE PRODUCTION THEREOF | Sumitomo Chemical Company, Limited (JP) | 2002-09-11 | — | — | EP | disclosed |
| EP-1103548-A1 | TRIAZOLONE DERIVATIVES, USE THEREOF, AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2001-05-30 | — | — | EP | disclosed |
| US-5545645-A | Heterocyclic derivatives in the treatment of ischaemia and related diseases | SYNTEX PHARMACEUTICALS, LIMITED (GB) | 1996-08-13 | — | — | US | disclosed |
| CN-1120838-A | Heterocyclic derivatives in the treatment of ischaemia and related diseases | SYNTEX PHARMA LTD (GB) | 1996-04-17 | — | — | CN | disclosed |
| EP-0693062-A1 | HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES | SYNTEX PHARMACEUTICALS LTD. (GB) | 1996-01-24 | — | — | EP | disclosed |
| US-5428037-A | Piperazine derivatives; calcium and sodium channel antagonists | SYNTEX PHARMACEUTICALS, LTD. (GB) | 1995-06-27 | — | — | US | disclosed |
| WO-1994024116-A1 | HETEROCYCLIC DERIVATIVES IN THE TREATMENT OF ISCHAEMIA AND RELATED DISEASES | SYNTEX PHARMACEUTICALS LIMITED (GB) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167193-A1 | Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof | CYP51A1, DPM1, CYP1A1 | HPGD 4076/4885PDCD1 2097/4885CD274 2180/4885 |
| US-20030119670-A1 | Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof | CYP51A1, DPM1, CYP1A1 | HPGD 4076/4885PDCD1 2097/4885CD274 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.